Increased 5α-reductase and normal 11β-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome

Journal of Pediatric Endocrinology and Metabolism

Volumn 13, Issue 3, 2000, Pages 253-259

  Chin, D ^a   Shackleton, C ^a   Prasad, V K ^a   Kohn, B ^a   David, R ^a   Imperato McGinley, J ^b   Cohen, H ^c   McMahon, D J ^d   Oberfield, Sharon E ^a,d,e  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d Columbia Univ School of Medicine ^*  (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

11 hydroxysteroid dehydrogenase; 5 reductase; Ovine corticotropin releasing factor; Polycystic ovarian syndrome; Steroid metabolism

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; STEROID 5ALPHA REDUCTASE; HSD11B1 PROTEIN, HUMAN; HYDROXYSTEROID DEHYDROGENASE; STEROID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; STEROID METABOLISM; TESTOSTERONE BLOOD LEVEL; AREA UNDER THE CURVE; CLINICAL TRIAL; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; URINE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADOLESCENT; ADULT; AREA UNDER CURVE; CORTICOTROPIN-RELEASING HORMONE; FEMALE; HUMANS; HYDROCORTISONE; HYDROXYSTEROID DEHYDROGENASES; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; STEROIDS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0033622064     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2000.13.3.253     Document Type: Article

References (32)

1. Frank S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-861.
2. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995; 16: 322-353.
3. Lobo RA. Polycystic ovary syndrome/hyperandrogenic chronic anovulation. Adv Endocrinol Metab 1995; 6: 167-191.
4. rd Annual Meeting of the American Society for the Reproductive Medicine, Cincinnati, OH, October 1997; abst O-087.
5. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, McCarthy M. Current developments in the molecular genetics of the polycystic ovary syndrome. Trends Endocrinol Metab 1998; 9: 51-54.
6. Legro RS. The genetics of polycystic ovary syndrome. Am J Med 1995; 98: 9S-16S.
7. DiMartino J. Insulin resistance in prepubertal African-American and Hispanic girls with premature adrenarche: A risk factor for polycystic ovary syndrome. Trends Endocrinol Metab 1998; 9: 78-82.
8. Ibañez L, Potau N, Virdis R, Zampolli M, Terzi C, Gussinye M, Carrascosa A, Vicens-Calvet E. Postpubertal outcome in girls diagnosed with premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76: 1599-1603.
9. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA 1995; 92: 10619-10623.
10. Gonzalez F. Adrenal involvement in polycystic ovary syndrome. Semin Reprod Endocr 1997; 15: 137-157.
11. Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome: Evidence of dysregulation of 11β-hydroxysteroid dehydrogenase. N Engl J Med 1994; 330: 460-465.
12. Stewart PM, Shackleton CHL, Beastall GH, Edwards CRW. 5α-Reductase activity in polycystic ovary syndrome. Lancet 1990; 335: 431-433.
13. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Owens JR, Haultine F, Merriam GR, eds, Polycystic Ovary Syndrome. Boston, MA: Blackwell, 1992; 377-384.
14. Palermo M, Gomez-Sanchez C, Roitman E, Shackleton CHL. Quantitation of cortisol and related 3-oxo-4-ene steroids in urine using gas chromatography/mass spectrometry with stable isotope-labeled internal standards. Steroids 1996; 61: 583-589.
15. Shackleton CHL. Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J Steroid Biochem Mol Biol 1993; 45: 127-140.
16. Chrousos GP, Schulte HM, Oldfield EH, Gold PW, Cutler GB Jr, Loriaux L. The corticotropin-releasing factor stimulation test: An aid in the evaluation of patients with Cushing's syndrome. N Engl J Med 1984; 310: 622-627.
17. Nicholson WE, Davis DR, Sherrill BJ, Orth DN. Rapid radioimmunoassay for corticotropin in unextracted human plasma. Clin Chem 1984; 30: 259-265.
18. Abraham GE, Buster JE, Teller RC. Radioimmunoassay of plasma cortisol. Anal Lett 1972; 5: 757-766.
19. Rubin DB. Multiple Imputation of Nonresponse in Surveys. New York: John Wiley and Sons, Inc. 1987.
20. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol 1961; 21: 1440-1447.
21. Luppa P, Burkhardt M, Jacob K, Kimmig R, Strowitzki T, Höss C, Weber MM, Engelhardt D, Lobo RA. Variations of steroid hormone metabolites in serum and urine in polycystic ovary syndrome after Nafarelin stimulation: Evidence for an altered corticoid excretion. J Clin Endocrinol Metab 1995; 80: 280-288.
22. Lanzone A, Petraglia F, Fulghesu AM, Ciampelli M, Caruso A, Mancuso S. Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome. Fert Steril 1995; 63: 1195-1199.
23. Carmina E, Lobo RA. Pituitary-adrenal responses to ovine corticotropin-releasing factor in polycystic ovary syndrome and in other hyperandrogenic patients. Gynecol Endocrinol 1990; 4: 225-232.
24. Apter D, Butzow T, Laughlin GA, Yen SSC. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: Relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab 1994; 79: 119-125.
25. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 1998; 83: 2317-2323.
26. Feuillan P, Pang S, Schürmeyer T, Avgerinos PC, Chrousos GP. The hypothalamic-pituitary-adrenal axis in partial (late-onset) 21-hydroxylase deficiency. J Clin Endocrinol Metab 1988; 67: 154-160.
27. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801-810.
28. Raven PW, Taylor NF. Evidence for independent modulation of human 11-HSD and 5α-reductase activities. Endocr Res 1996; 22: 811-815.
29. Horton R, Pasupuletti V, Antonipillai I. Androgen induction of steroid 5α-reductase may be mediated via insulin-like growth factor-I. Endocrinology 1993; 133: 447-451.
30. Carmina E, Stanczyk FZ, Morris RS, Lee PDK, Savjani G, Lobo RA. Altered regulation of insulin-like growth factor binding protein-I in patients with polycystic ovary syndrome. J Soc Gynecol Invest 1995; 2: 743-747.
31. nd Annual Meeting of the American Society for Reproductive Medicine, Boston, 1996; PS193.
32. Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells. Fert Steril 1998; 69: 335-340.